A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

• Drug: PD-0332991 alone
  
  PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.
  Other Name: PD-0332991, palbociclib
• Drug: Tamoxifen 60 mg
  
  On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).
• Drug: Tamoxifen 20 mg
  
  On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.
• Drug: PD-0332991 combination
  
  PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.
  Other Name: PD-0332991, palbociclib

Inclusion Criteria:

• Healthy male between the ages of 18 and 55 years of age inclusive
• Body mass index (BMI) between 17.5 and 30.5 kg/m2
• Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

• a positive urine drug screen
• a supine systolic blood pressure >140 mm Hg, or diastolic blood pressure >90 mm H.
• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.